An international research team has identified a new family of bacteria that could be used to identify and treat children’s urinary tract infections.
The research team identified the microorganisms as Pseudomonas aeruginosa and Clostridium difficile, which cause urinary tract infection.
The findings were published in the journal Nature.
The team found that the bacteria are capable of breaking down and digesting the intestinal bacteria that cause UTIs.
They also noted that the microorganism can be isolated from human faeces and can be found in faecal samples from people with UTIs or who have recently had an UTI.
The bacteria can be identified by isolating them in a human sample, which is known as a stool sample.
They have been used in UTIs in humans before and in animal models to identify bacteria that trigger UTIs, but this is the first time they have been found in a live human.
“We have shown that these bacteria can live in our faecia, and this allows us to identify them and isolate them,” said study lead author Jules Buitel, a microbiologist at the University of Exeter in England.
The findings have important implications for UTIs and the treatment of UTIs at the hospital.
“There is no cure for UTI, but there is a treatment and it is effective,” Buitels said.
“It has not been used yet in humans, but it has been used successfully in animals and we are looking at the possibility of that in humans.”
The researchers also said they could use the findings to help identify people who are at risk of UTI in the future.
“This is very exciting because this could help people who have UTIs with a better diagnosis,” Buell said.
Microbiologist Jules Bell said the discovery of these microorganisms is important because it could help us better understand UTIs by looking at how they are broken down in the human gut.
He added that more research is needed to confirm that the bacterial species are capable.
“There are many people with severe UTIs who do not get better, but some of them are still getting better.
I think that it is important to find out whether these bacteria have this capacity,” Bell said.
The study was supported by a grant from the Department of Health, Universities and Science, the European Research Council, the National Institutes of Health (NIEHS) and the UK Medical Research Council.